In fiscal 2025, which ended Dec 28, 2025, Johnson & Johnson generated $24.5 billion of cash from operations, up 1.1% from the year before. It spent $4.8 billion on capital expenditures. That left free cash flow of $19.7 billion. The company returned $6.0 billion in share buybacks to shareholders.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 27, 2026
|
FY 2025
Dec 28, 2025
|
FY 2024
Dec 29, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Jan 1, 2023
|
FY 2021
Jan 2, 2022
|
FY 2020
Jan 3, 2021
|
FY 2019
Dec 29, 2019
|
FY 2018
Dec 30, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Jan 1, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Depreciation and amortization |
8,091
+9.5%
|
7,503
+2.2%
|
7,339
-2.0%
|
7,486
+7.4%
|
6,970
-5.7%
|
7,390
+2.2%
|
7,231
+3.2%
|
7,009
+1.2%
|
6,929
+22.8%
|
5,642
+50.3%
|
3,754
+0.2%
|
| Stock-based compensation |
1,424
+11.0%
|
1,354
+15.1%
|
1,176
+1.2%
|
1,162
+2.1%
|
1,138
+0.3%
|
1,135
+12.9%
|
1,005
+2.9%
|
977
-0.1%
|
978
+1.7%
|
962
+9.6%
|
878
+0.5%
|
| Operating cash flow |
26,159
+8.1%
|
24,530
+1.1%
|
24,266
+6.5%
|
22,791
+7.5%
|
21,194
-9.5%
|
23,410
-0.5%
|
23,536
+0.5%
|
23,416
+5.5%
|
22,201
+5.4%
|
21,056
+12.2%
|
18,767
-4.1%
|
| Investing | |||||||||||
| Capital expenditures |
5,569
+20.9%
|
4,832
+9.2%
|
4,424
-2.6%
|
4,543
+13.3%
|
4,009
+9.8%
|
3,652
+9.1%
|
3,347
-4.3%
|
3,498
-4.7%
|
3,670
+11.9%
|
3,279
+1.6%
|
3,226
-6.8%
|
| Investing cash flow |
-9,344
+54.2%
|
-23,588
-26.8%
|
-18,599
-2218.3%
|
878
+107.1%
|
-12,371
-42.5%
|
-8,683
+58.3%
|
-20,825
-236.2%
|
-6,194
-95.6%
|
-3,167
+78.7%
|
-14,868
-212.3%
|
-4,761
+38.4%
|
| Financing | |||||||||||
| Debt issued |
0
-100.0%
|
9,138
+37.2%
|
6,660
|
0
-100.0%
|
2
-60.0%
|
5
-99.9%
|
7,431
+247600.0%
|
3
-40.0%
|
5
-99.9%
|
8,992
-25.1%
|
12,004
+15905.3%
|
| Debt repaid |
—
|
1,757
+20.9%
|
1,453
-6.3%
|
1,551
-27.3%
|
2,134
+18.4%
|
1,802
+69.4%
|
1,064
-62.3%
|
2,823
+81.5%
|
1,555
-12.5%
|
1,777
-20.1%
|
2,223
+3169.1%
|
| Short-term debt issued |
19,335
+38.4%
|
14,586
-4.5%
|
15,277
+11.2%
|
13,743
-14.8%
|
16,134
+707.9%
|
1,997
-41.1%
|
3,391
+8594.9%
|
39
-51.2%
|
80
-90.8%
|
869
+682.9%
|
111
-95.4%
|
| Short-term debt repaid |
18,116
+55.7%
|
12,330
+30.3%
|
9,463
-58.8%
|
22,973
+250.7%
|
6,550
+450.4%
|
1,190
-55.3%
|
2,663
+2563.0%
|
100
-96.0%
|
2,479
+86.4%
|
1,330
-34.1%
|
2,017
+93.2%
|
| Stock buybacks |
7,882
+82.8%
|
5,953
+144.8%
|
2,432
-51.9%
|
5,054
-16.3%
|
6,035
+74.6%
|
3,456
+7.3%
|
3,221
-52.3%
|
6,746
+15.0%
|
5,868
-7.7%
|
6,358
-29.2%
|
8,979
+69.7%
|
| Financing cash flow |
-18,149
-229.4%
|
-5,539
-76.9%
|
-3,132
+80.2%
|
-15,825
-78.4%
|
-8,871
+36.8%
|
-14,047
-129.5%
|
-6,120
+66.0%
|
-18,015
+2.7%
|
-18,510
-141.2%
|
-7,673
+10.3%
|
-8,551
+23.2%
|
| Change in cash | |||||||||||
| Effect of exchange rate |
13
+165.0%
|
201
+169.6%
|
-289
-158.0%
|
-112
+64.1%
|
-312
-75.3%
|
-178
-300.0%
|
89
+1088.9%
|
-9
|
—
|
—
|
—
|
| Net change in cash |
-1,321
+24.5%
|
-4,396
-295.7%
|
2,246
-71.0%
|
7,732
+2247.8%
|
-360
-171.7%
|
502
+115.1%
|
-3,320
-314.0%
|
-802
|
—
|
—
|
—
|
| Free cash flow |
20,590
+5.1%
|
19,698
-0.7%
|
19,842
+8.7%
|
18,248
+6.2%
|
17,185
-13.0%
|
19,758
-2.1%
|
20,189
+1.4%
|
19,918
+7.5%
|
18,531
+4.2%
|
17,777
+14.4%
|
15,541
-3.5%
|
| Per share | |||||||||||
| Free cash flow per share |
8.42
+4.2%
|
8.11
-0.7%
|
8.17
+14.6%
|
7.13
+10.5%
|
6.45
-12.7%
|
7.39
-2.3%
|
7.56
+1.9%
|
7.42
+9.3%
|
6.79
+4.9%
|
6.48
+16.2%
|
5.57
-2.7%
|
| Dividend per share |
5.28
+3.9%
|
5.14
+4.7%
|
4.91
+4.5%
|
4.70
+5.6%
|
4.45
+6.2%
|
4.19
+5.3%
|
3.98
+6.1%
|
3.75
+5.9%
|
3.54
+6.6%
|
3.32
+5.4%
|
3.15
+6.8%
|
| Shareholder returns | |||||||||||
| Returned to shareholders |
7,882
|
5,953
|
2,432
|
5,054
|
6,035
|
3,456
|
3,221
|
6,746
|
5,868
|
6,358
|
8,979
|
| Share of free cash flow |
38.28%
|
30.22%
|
12.26%
|
27.70%
|
35.12%
|
17.49%
|
15.95%
|
33.87%
|
31.67%
|
35.77%
|
57.78%
|
| Ratios | |||||||||||
| Free cash flow margin |
20.73%
|
20.91%
|
22.34%
|
21.43%
|
21.48%
|
25.09%
|
24.45%
|
24.27%
|
22.71%
|
—
|
—
|
| Capital expenditures to revenue |
5.61%
|
5.13%
|
4.98%
|
5.33%
|
5.01%
|
4.64%
|
4.05%
|
4.26%
|
4.50%
|
—
|
—
|
| Stock-based compensation to revenue |
1.43%
|
1.44%
|
1.32%
|
1.36%
|
1.42%
|
1.44%
|
1.22%
|
1.19%
|
1.20%
|
—
|
—
|
| Cash conversion |
1.63x
|
0.92x
|
1.73x
|
0.65x
|
1.18x
|
1.12x
|
1.60x
|
1.55x
|
1.45x
|
16.20x
|
1.13x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JNJ (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- NJ
- Headquarters
- New Brunswick, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 200406
- Former names
- JOHNSON & JOHNSON ET AL (until Jan 23, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.